PTC Therapeutics (PTCT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.50 (-0.99%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of PTC Therapeutics (PTCT)
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Key Insights

Critical company metrics and information

  • Share Price

    $49.86

  • Market Cap

    $3.85 Billion

  • Total Outstanding Shares

    77.13 Million Shares

  • Total Employees

    995

  • Dividend

    No dividend

  • IPO Date

    June 20, 2013

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.ptcbio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$353.96 Million
Net Cash Flow, Continuing$353.96 Million
Net Cash Flow From Investing Activities$-317.95 Million
Net Cash Flow From Financing Activities$849.88 Million
Net Cash Flow From Operating Activities, Continuing$-177.97 Million
Net Cash Flow From Investing Activities, Continuing$-317.95 Million
Net Cash Flow From Operating Activities$-177.97 Million
Net Cash Flow From Financing Activities, Continuing$849.88 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$-453.20 Million
Preferred Stock Dividends And Other Adjustments$0.00
Basic Earnings Per Share$5.94
Costs And Expenses$1.33 Billion
Benefits Costs and Expenses$1.33 Billion
Net Income/Loss$-453.20 Million
Basic Average Shares$76.94 Million
Selling, General, and Administrative Expenses$292.52 Million
Diluted Earnings Per Share$5.94
Income Tax Expense/Benefit$27.73 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Income/Loss$-134.36 Million
Revenues$900.66 Million
Operating Expenses$1.04 Billion
Diluted Average Shares$76.94 Million
Other Operating Expenses$211.44 Million
Income/Loss From Continuing Operations Before Tax$-425.47 Million
Research and Development$531.06 Million
Income/Loss From Continuing Operations After Tax$-453.20 Million
Net Income/Loss Available To Common Stockholders, Basic$-453.20 Million
Income Tax Expense/Benefit, Deferred$4.01 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Inventory$35.67 Million
Equity$-1.05 Billion
Intangible Assets$330.37 Million
Other Current Assets$1.05 Billion
Assets$1.84 Billion
Noncurrent Assets$560.69 Million
Noncurrent Liabilities$2.29 Billion
Wages$46.21 Million
Equity Attributable To Parent$-1.05 Billion
Other Current Liabilities$551.21 Million
Fixed Assets$63.17 Million
Current Assets$1.28 Billion
Accounts Receivable$199.98 Million
Liabilities And Equity$1.84 Billion
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$13.29 Million
Liabilities$2.90 Billion
Current Liabilities$610.71 Million
Other Non-current Assets$167.14 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.